Drugs / Fosmanogepix
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT06961708 | Apr → Jul 2025 | — | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT05582187 | Oct 2022 → Oct 2025 | — | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT04166669 | Nov 2019 → Mar 2020 | fungal infectious disease | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT04804059 | Aug → Sep 2018 | fungal infectious disease | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT03333005 | Nov 2017 → Oct 2018 | acute myeloid leukemia | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT02957929 | Oct 2016 → Apr 2017 | fungal infectious disease | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT02956499 | May 2016 → Jul 2017 | fungal infectious disease | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04240886 | Jan 2020 → Mar 2022 | fungal infectious disease | Basilea Pharmaceutica | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04148287 | Dec 2019 → Nov 2020 | candidemia | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 2 | NCT03604705 | Oct 2018 → Mar 2020 | candidemia | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06925321 | Aug 2025 → Feb 2028 expected | fungal infectious disease | Basilea Pharmaceutica | Recruiting | No outcome recorded |
| Phase 3 | NCT05421858 | Dec 2024 → Jan 2028 expected | candidemia | Basilea Pharmaceutica | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06433128 | — | fungal infectious disease | Basilea Pharmaceutica | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-16 | Basilea Pharmaceutica | Results Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025 basilea.com ↗
More than 250 patients from 11 countries with serious or life-threatening invasive fungal infections, who progressed on antifungal standard-of-care treatment, experienced treatment-limiting toxicities, or had infections with resistant fungal pathogens, received fosmanogepix via expanded access to date (NCT06433128). |
All press releases naming this drug 8 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fosmanogepix | “Fosmanogepix [FMGX; active form manogepix (MGX)], a novel antifungal, is currently being studied for the treatment of invasive fungal diseases caused by Candida spp.,...” PMID 39012090 ↗ Jul 20247“Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate” PMID 36988461 ↗ Mar 2023 |
| Known as | APX001 | “Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate” PMID 36988461 ↗ Mar 2023 |
| Known as | E1211 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297591 ↗ |
| Known as | FMGX | “Fosmanogepix [FMGX; active form manogepix (MGX)], a novel antifungal, is currently being studied for the treatment of invasive fungal diseases caused by Candida spp.,...” PMID 39012090 ↗ Jul 20243“Fosmanogepix (FMGX) inhibits glycosylphosphatidylinositol anchored cell wall transfer protein 1, essential for anchoring mannoproteins to fungal cell wall, critical for host invasion.” PMID 40203286 ↗ Dec 2025 “Fosmanogepix [FMGX; active moiety manogepix (MGX)] targets glycosylphosphatidylinositol-anchored mannoprotein synthesis and maturation, essential for fungal virulence.” PMID 38757982 ↗ May 2024 “Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate” PMID 36988461 ↗ Mar 2023 |
| Known as | PF 07842805 | “A Phase 1, Open-label, Single-dose, Parallel Cohort Study to Assess the Pharmacokinetics and Safety of Fosmanogepix (PF 07842805) in Adult Participants With Varying Degrees of...” NCT05582187 ↗ |
| Action | Inhibit | “interferes with cell wall synthesis by targeting fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1” PMID 36988461 ↗ Mar 2023 |
| Modality | Small molecule | — CHEMBL4297591 ↗ |
| Route | Intravenous | “Administered by Intravenous Infusion” NCT02956499 ↗ |
| Target | GWT1 | “a novel Gwt-1 inhibitor” PMID 39012090 ↗ Jul 2024 |